Chronic Obstructive Pulmonary Disease Market Expected to rise, 2034 | AstraZeneca/Circassia Pharmaceuticals Inc., GlaxoSmithKline/Theravance, Inc/Innoviva, Chiesi Farmaceutici, Sunovion Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals, Sanofi/Regener

The Chronic Obstructive Pulmonary Disease market growth is driven by factors like increase in the prevalence of Chronic Obstructive Pulmonary Disease, investments in research and development, entry of emerging therapies during the study period 2020-2034.

The Chronic Obstructive Pulmonary Disease market report also offers comprehensive insights into the Chronic Obstructive Pulmonary Disease market size, share, Chronic Obstructive Pulmonary Disease epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Chronic Obstructive Pulmonary Disease market size growth forward.

Some of the key highlights from the Chronic Obstructive Pulmonary Disease Market Insights Report:

Several key pharmaceutical companies, including AstraZeneca/Circassia Pharmaceuticals Inc., GlaxoSmithKline/Theravance, Inc/Innoviva, Chiesi Farmaceutici, Sunovion Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals, Sanofi/Regeneron Pharmaceuticals, United Therapeutics, Verona Pharma PLC, Inmunotek, Novartis, Organicell Regenerative Medicine, Vertex Pharmaceuticals Incorporated, Pulmotect Inc., Genentech, Mereo BioPharma, Biomarck Pharmaceuticals, and others, are developing novel products to improve the Chronic Obstructive Pulmonary Disease treatment outlook.
The Chronic Obstructive Pulmonary Disease (COPD) market was valued at USD 16,075 million in 2023 and is expected to see steady growth throughout the forecast period (2024-2034). This expansion is largely driven by an increase in diagnosed cases and the introduction of new therapies.
According to DelveInsight's analysis, approximately 41% of the total diagnosed prevalent COPD cases in the 7MM were in the United States. In 2023, estimates indicate that the EU4 and the UK collectively accounted for around 18.6 million diagnosed cases.
The COPD market in the 7MM is primarily segmented into three treatment categories: Monotherapies (including LABA, LAMA, and others), Double Combination Therapies (such as LABA + ICS, LABA + LAMA, and other combinations), and Triple Combination Therapies (LABA + LAMA + ICS). Among these, Double Combination Therapies generated the highest revenue, amounting to approximately USD 8,803 million in 2023.
The overall market for COPD treatments is expected to grow further during the forecast period, driven by the introduction of novel and more effective therapies such as Itepekimab (SAR440340/REGN3500), FASENRA (benralizumab), and NUCALA (mepolizumab), among others.
In October 2024, FDA approves first monoclonal antibody for COPD
In September 2024, Sanofi and Regeneron's Dupixent Snags First Biologic Approval in COPD.
In May 2024, AstraZeneca presented its latest research on major respiratory and immune-mediated diseases at ATS 2024, highlighting the strength of its pipeline and portfolio, including studies on benralizumab for COPD treatment.
As per DelveInsight analysis, the Chronic Obstructive Pulmonary Disease market is anticipated to witness growth at a considerable CAGR

Strategise your business goals by understanding market dynamics @ Chronic Obstructive Pulmonary Disease Market Landscape https://www.delveinsight.com/report-store/chronic-obstructive-pulmonary-disease-copd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Chronic Obstructive Pulmonary Disease Overview

Chronic Obstructive Pulmonary Disease (COPD) is a prevalent, preventable, and treatable condition marked by persistent respiratory symptoms and airflow limitation. This occurs due to structural abnormalities in the airways and/or alveoli, typically resulting from prolonged exposure to harmful particles or gases. The development of COPD involves complex pathological mechanisms, leading to distinct subgroups with unique characteristics and progression patterns. These variations contribute to differences in exacerbation rates, airflow restriction, and lung function impairment. Managing this diversity effectively remains a major challenge in COPD treatment.

Do you know the treatment paradigms for different countries? Download our Chronic Obstructive Pulmonary Disease Market Sample Report https://www.delveinsight.com/sample-request/chronic-obstructive-pulmonary-disease-copd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Chronic Obstructive Pulmonary Disease Epidemiology Insights

According to DelveInsight's analysis, approximately 44.2 million diagnosed prevalent cases of COPD were reported in the 7MM in 2023.
Among these countries, the United States had the highest diagnosed prevalence of COPD. DelveInsight estimates that there were around 18.3 million diagnosed cases in the U.S. in 2023, with this number expected to rise during the forecast period. This increase is attributed to factors such as the growing prevalence of smoking, advancements in diagnostic methods, and greater awareness among patients.

Chronic Obstructive Pulmonary Disease Epidemiology Segmentation

DelveInsight's Chronic Obstructive Pulmonary Disease market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Chronic Obstructive Pulmonary Disease historical patient pools and forecasted Chronic Obstructive Pulmonary Disease patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Chronic Obstructive Pulmonary Disease Market report proffers epidemiological analysis for the study period 2020-34 in the 7MM segmented into:

Chronic Obstructive Pulmonary Disease Prevalence
Age-Specific Chronic Obstructive Pulmonary Disease Prevalence
Gender-Specific Chronic Obstructive Pulmonary Disease Prevalence
Diagnosed and Treatable Cases of Chronic Obstructive Pulmonary Disease

Visit for more @ Chronic Obstructive Pulmonary Disease Epidemiological Insights https://www.delveinsight.com/report-store/chronic-obstructive-pulmonary-disease-copd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Chronic Obstructive Pulmonary Disease Market Outlook

Chronic Obstructive Pulmonary Disease (COPD) is a widespread, preventable, and treatable lung condition affecting both men and women globally. It is characterized by airflow limitation due to airway narrowing, inflammation, mucus buildup, and lung tissue destruction. COPD shares symptoms with asthma, such as coughing, wheezing, and breathing difficulties, and some individuals may have both conditions.

While mild cases may require minimal treatment beyond smoking cessation, more advanced stages can be managed with therapies that control symptoms, slow disease progression, and reduce complications. Treatment aims to improve breathing and overall quality of life through a combination of medications, lifestyle modifications, and alternative approaches. COPD management is stage-specific, focusing on symptom relief and infection prevention.

Preventive measures, particularly smoking cessation, are crucial in slowing disease progression. Regular physical activity can also strengthen respiratory muscles and enhance well-being. Pharmacological treatment includes maintenance medications (such as inhaled corticosteroids, long-acting beta-agonists, and combination therapies) and reliever medications (such as short-acting beta-agonists, oral corticosteroids, and nebulized treatments).
Chronic Obstructive Pulmonary Disease Emerging Drugs
Duaklir Pressair (aclidinium/formoterol fumarate): AstraZeneca
DUPIXENT (Dupilumab): Regeneron Pharmaceuticals/Sanofi
Chronic Obstructive Pulmonary Disease Emerging Drugs
Itepekimab (SAR440340/REGN3500): Sanofi/Regeneron Pharmaceuticals
FASENRA (benralizumab): AstraZeneca
Chronic Obstructive Pulmonary Disease Key Companies
AstraZeneca/Circassia Pharmaceuticals Inc., GlaxoSmithKline/Theravance, Inc/Innoviva, Chiesi Farmaceutici, Sunovion Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals, Sanofi/Regeneron Pharmaceuticals, United Therapeutics, Verona Pharma PLC, Inmunotek, Novartis, Organicell Regenerative Medicine, Vertex Pharmaceuticals Incorporated, Pulmotect Inc., Genentech, Mereo BioPharma, Biomarck Pharmaceuticals, and others
For more information, visit Chronic Obstructive Pulmonary Disease Market Analysis, Patient Pool, and Emerging Therapies https://www.delveinsight.com/sample-request/chronic-obstructive-pulmonary-disease-copd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Scope of the Chronic Obstructive Pulmonary Disease Market Report:

11 Years Forecast
7MM Coverage
Descriptive overview of Chronic Obstructive Pulmonary Disease, causes, signs and symptoms, diagnosis, treatment
Comprehensive insight into Chronic Obstructive Pulmonary Disease epidemiology in the 7MM
Chronic Obstructive Pulmonary Disease marketed and emerging therapies
Chronic Obstructive Pulmonary Disease companies
Chronic Obstructive Pulmonary Disease market drivers and barriers

Table of Contents:

1 Chronic Obstructive Pulmonary Disease Market Key Comprehensive Insights
2 Chronic Obstructive Pulmonary Disease Market Report Introduction
3 Competitive Intelligence Analysis for Chronic Obstructive Pulmonary Disease
4 Chronic Obstructive Pulmonary Disease Market Analysis Overview at a Glance
5 Executive Summary of Chronic Obstructive Pulmonary Disease
6 Chronic Obstructive Pulmonary Disease Epidemiology and Market Methodology
7 Chronic Obstructive Pulmonary Disease Epidemiology and Patient Population
8 Chronic Obstructive Pulmonary Disease Patient Journey
9 Chronic Obstructive Pulmonary Disease Treatment Algorithm, Chronic Obstructive Pulmonary Disease Current Treatment, and Medical Practices
10 Key Endpoints in Chronic Obstructive Pulmonary Disease Clinical Trials
11 Chronic Obstructive Pulmonary Disease Marketed Therapies
12 Chronic Obstructive Pulmonary Disease Emerging Therapies
13 Chronic Obstructive Pulmonary Disease: 7 Major Market Analysis
14 Attribute analysis
15 Access and Reimbursement Overview of Chronic Obstructive Pulmonary Disease
16 Chronic Obstructive Pulmonary Disease Market Key Opinion Leaders Reviews
18 Chronic Obstructive Pulmonary Disease Market Drivers
19 Chronic Obstructive Pulmonary Disease Market Barriers
20 SWOT Analysis
21 Disclaimer
22 DelveInsight Capabilities
23 About DelveInsight

Related Reports:

Chronic Obstructive Pulmonary Disease Epidemiology 2034

DelveInsight's "Chronic Obstructive Pulmonary Disease - Epidemiology Forecast to 2034" report delivers an in-depth understanding of the disease, historical and forecasted Chronic Obstructive Pulmonary Disease epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Chronic Obstructive Pulmonary Disease Pipeline 2024

"Chronic Obstructive Pulmonary Disease Pipeline Insights, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Chronic Obstructive Pulmonary Disease market. A detailed picture of the Chronic Obstructive Pulmonary Disease pipeline landscape is provided, which includes the disease overview and Chronic Obstructive Pulmonary Disease treatment guidelines.

Contact Info:
Kritika Rehani
Assistant Manager, Marketing & Branding
krehani@delveinsight.com
info@delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.